Oncopeptides
ONCO | ST
Overview
Corporate Details
- ISIN(s):
- SE0009414576 (+4 more)
- LEI:
- 549300J9WWQ5CBYQ1M77
- Country:
- Sweden
- Address:
- Luntmakargatan 46, 111 37 Stockholm
- Website:
- https://www.oncopeptides.com/en
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Oncopeptides AB is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers, particularly hematological diseases. Founded in 2000, the company leverages its proprietary Peptide Drug Conjugate technology platforms to develop innovative treatments. Its lead product, Pepaxti® (melflufen), is a treatment for adult patients with relapsed refractory multiple myeloma (RRMM). Oncopeptides is actively commercializing Pepaxti in Europe and conducts real-world evidence studies to support the drug's effectiveness and tolerability in clinical practice. The company's mission is to address significant unmet medical needs and provide hope to cancer patients through scientific innovation.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Oncopeptides.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-13 10:32 |
Major Shareholding Notification
|
Swedish | 10.6 KB | |
| 2025-08-07 10:08 |
Major Shareholding Notification
|
Swedish | 10.5 KB | |
| 2025-08-05 16:06 |
Major Shareholding Notification
|
Swedish | 10.4 KB | |
| 2025-07-22 10:06 |
Major Shareholding Notification
|
Swedish | 10.3 KB | |
| 2025-07-18 11:39 |
Major Shareholding Notification
|
Swedish | 10.3 KB | |
| 2025-07-14 13:43 |
Major Shareholding Notification
|
Swedish | 10.3 KB | |
| 2025-07-09 11:30 |
Earnings Release
Oncopeptides announces net sales for Q2 2025
|
English | 76.9 KB | |
| 2025-07-09 11:30 |
Earnings Release
Oncopeptides offentliggör försäljning för andra kvartalet 2025
|
Swedish | 77.7 KB | |
| 2025-05-22 14:00 |
Post-Annual General Meeting Information
Kommuniké från årsstämma i Oncopeptides AB (publ)
|
Swedish | 72.0 KB | |
| 2025-05-22 14:00 |
Post-Annual General Meeting Information
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
|
English | 72.2 KB | |
| 2025-05-15 08:00 |
Quarterly Report
|
Swedish | 517.8 KB | |
| 2025-05-15 08:00 |
Quarterly Report
|
English | 486.8 KB | |
| 2025-04-28 15:30 |
Annual Report (ESEF)
|
Swedish | 6.6 MB | |
| 2025-04-22 12:14 |
Major Shareholding Notification
|
Swedish | 8.7 KB | |
| 2025-03-03 15:26 |
Major Shareholding Notification
|
Swedish | 7.8 KB |
Automate Your Workflow. Get a real-time feed of all Oncopeptides filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Oncopeptides via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-04-15 | David Augustsson | Other | Buy | 1,250 | 6,350.00 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 1,250 | 6,312.50 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 438 | 2,225.04 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 60 | 303.60 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 2 | 10.02 SEK |
| 2023-09-08 | David Augustsson | Other | Buy | 2,296 | 17,706.75 SEK |
| 2023-08-10 | David Augustsson | Other | Buy | 1,704 | 14,995.20 SEK |
| 2023-05-04 | Nicolaas Bakker | Other | Buy | 5,000 | 42,380.00 SEK |
| 2022-10-10 | Nicolaas Bakker | Other | Buy | 15,000 | 164,400.00 SEK |
| 2022-08-30 | Per Wold-Olsen | Other | Buy | 2,050 | 55,350.00 SEK |
